Biography for Prof GUS GAZZARD MD MA(Cantab) MBBChir FRCOphth
Gus Gazzard completed undergraduate and medical school training at Corpus Christi College, Cambridge University. He was made a Consultant in the Glaucoma Service at Moorfields Eye Hospital in 2009 after a Clinical Fellowship at Moorfields 2006-08 and a Research Fellowship with Prof Peng Khaw in Singapore 1999-2002, where he ran and established several clinical trials investigating the surgical treatments of glaucoma (including the Singapore-5FU and ACLIPS trials, both published in Ophthalmology).
In 2019 he was appointed a UCL Professor of Ophthalmology (Glaucoma Studies) at the Institute of Ophthalmology, University College London and is currently Director of the Glaucoma service at Moorfields.
Gus’ has an interest in the drop-free treatments of glaucoma with current research into selective laser trabeculoplasty (SLT) and Minimally Invasive Glaucoma procedures (‘MIGS’). He is training surgeons in the use of the iStent, Preserflo / InnFocus MicroShunt and Hydrus devices. Gus has established two large, 6-year studies of laser treatment in the UK and China and is co-ordinating a number of Cochrane Collaboration Reports and defining outcomes for Minimally Invasive Glaucoma Surgical devices.
In 2012 he established, as Chief Investigator, the 6-year NIHR-HTA funded (£2m) multi-centre LiGHT trial of selective laser trabeculoplasty which completed recruitment of 718 subjects on target, on-time and is published in The Lancet 2019. He has since raised over £500k to support this and other projects. The sister trial, LiGHT-China, recently finished enrolment of 769 subjects in collaboration with Sun Yat Sen University, Guangzhou.
Gus’ clinical research interests include angle closure glaucoma, selective laser trabeculoplasty, randomised controlled trials of glaucoma treatments and anterior segment imaging. He collaborated on the TAGS trial of surgery for advanced glaucoma; was a member of the EAGLE Study Group (an international multi-centre study of early lens extraction in angle-closure); on the advisory board for the ZAP trial (assessing preventative laser iridotomy); co-founder of the European Glaucoma Society Special Interest Group in Angle Closure, contributor to the EGS Glaucoma Treatment Guidelines, co-chair of the EGS external-relations committee and currently working on the Royal College of Ophthalmologists Angle Closure Guidelines.
He sits on the awards panel of the BCPB (British Campaign to Prevent Blindness) and the clinical advisory board of Glaucoma UK and is a Trustee of the Friends of Moorfields Charity.